Mineralys Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Mineralys Therapeutics (MLYS).

Price Target Range — 8 Quarters

Analyst Consensus — 8 Analysts

7Buy

1Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$49Upside to Avg. PT+108.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Apr 27, 2026	TD Cowen	Tara Bancroft	Initiate	Buy	—
Mar 13, 2026	B of A Securities	Greg Harrison	PT Raise	Buy	$46→$51
Dec 19, 2025	Stifel	Annabel Samimy	PT Raise	Buy	$45→$52
Nov 12, 2025	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$52→$56
Nov 11, 2025	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$50→$55
Oct 30, 2025	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$42→$52
Sep 11, 2025	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$26→$50
Sep 9, 2025	Goldman Sachs	Richard Law	PT Raise	Buy	$32→$52
Sep 8, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$42
Sep 3, 2025	Jefferies	Dennis Ding	PT Raise	Hold	$15→$26
Aug 28, 2025	B of A Securities	Greg Harrison	PT Raise	Buy	$38→$43
Aug 13, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$42
Jun 17, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$42
Jun 11, 2025	Jefferies	Dennis Ding	Initiate	Hold	$15
May 13, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$42
Apr 2, 2025	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$30→$42
Mar 10, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$30
Feb 24, 2025	Guggenheim	Seamus Fernandez	Maintained	Buy	—
Feb 13, 2025	Goldman Sachs	Richard Law	PT Cut	Buy	$28→$24
Feb 13, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$30

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
TD Cowen Initiates Coverage On Mineralys Therapeutics with Buy Rating

TD Cowen analyst Tara Bancroft initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51

B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $46 to $51.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $45 to $52.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $52 to $56.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $50 to $55.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $42 to $52.

Benzinga Newsdesk

Mineralys Therapeutics Inc

Mineralys Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
TD Cowen Initiates Coverage On Mineralys Therapeutics with Buy Rating

PRO
B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51

PRO
Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

PRO
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56

PRO
Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55

PRO
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

People Also Watch

People Also Watch

Mineralys Therapeutics Inc

Mineralys Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTD Cowen Initiates Coverage On Mineralys Therapeutics with Buy Rating

PROB of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51

PROStifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

PROHC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56

PROWells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55

PROHC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

People Also Watch

People Also Watch

PRO
TD Cowen Initiates Coverage On Mineralys Therapeutics with Buy Rating

PRO
B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51

PRO
Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

PRO
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56

PRO
Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55

PRO
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52